Have a personal or library account? Click to login
SCM-198 Can Regulate Autophagy Through the Bax/Bcl-2/TLR4 Pathway to Alleviate Renal Ischemia-Reperfusion Injury Cover

SCM-198 Can Regulate Autophagy Through the Bax/Bcl-2/TLR4 Pathway to Alleviate Renal Ischemia-Reperfusion Injury

The EuroBiotech Journal
Volume 5 (2021): Issue 4 (October 2021)
By: Ersen Eraslan,  Burak Bircan,  Ayhan Tanyeli,  Mustafa Can Güler,  Yasin Bayır and  Serdar Altun  
Open Access
|Oct 2021

Figures & Tables

Figure 1

SCM-198 chemical structure.
SCM-198 chemical structure.

Figure 2

Effects of SCM-198 on kidney functions. (A) Urea and (B) Cre levels. *P<0.05 compared to the control and DMSO groups, ϕP<0.05 compared to the I/R group.
Effects of SCM-198 on kidney functions. (A) Urea and (B) Cre levels. *P<0.05 compared to the control and DMSO groups, ϕP<0.05 compared to the I/R group.

Figure 3

Effects of SCM- 198 on inflammatory cytokines. (A) TNF-α, (B) IL-1β and (C) IL- 18 levels. *P<0.05 compared to control and DMSO groups, ϕP<0.05 compared to I/R group.
Effects of SCM- 198 on inflammatory cytokines. (A) TNF-α, (B) IL-1β and (C) IL- 18 levels. *P<0.05 compared to control and DMSO groups, ϕP<0.05 compared to I/R group.

Figure 4

Changes in kidney damage biomarkers in the kidney I/ R model (A) NGAL, (B) KIM-1, and (C) PCX levels. *P<0.05 compared to control and DMSO groups, ϕP<0.05 compared to I/R group.
Changes in kidney damage biomarkers in the kidney I/ R model (A) NGAL, (B) KIM-1, and (C) PCX levels. *P<0.05 compared to control and DMSO groups, ϕP<0.05 compared to I/R group.

Figure 5

(A) Control group, LC3B immunonegativity (B) DMSO group, LC3B immunonegativity (C) I/R group, moderate LC3B immunopositivity was observed in renal tubule epithelial cells (arrowhead), (D) SCM-198 group, mild LC3B immunopositivity was detected in renal tubular epithelial cells (arrowhead).
(A) Control group, LC3B immunonegativity (B) DMSO group, LC3B immunonegativity (C) I/R group, moderate LC3B immunopositivity was observed in renal tubule epithelial cells (arrowhead), (D) SCM-198 group, mild LC3B immunopositivity was detected in renal tubular epithelial cells (arrowhead).

Figure 6

(A) Control group, Beclin-1 immunonegativity, (B) DMSO group, Beclin-1 immunonegativity, (C) I/R group, moderate Beclin-1 immunopositivity in renal tubule epithelial cells (arrowhead), (D) SCM -198 group, mild Beclin-1 immunopositivity in renal tubule epithelial cells (arrowhead).
(A) Control group, Beclin-1 immunonegativity, (B) DMSO group, Beclin-1 immunonegativity, (C) I/R group, moderate Beclin-1 immunopositivity in renal tubule epithelial cells (arrowhead), (D) SCM -198 group, mild Beclin-1 immunopositivity in renal tubule epithelial cells (arrowhead).

Figure 7

(A) Control group, TLR4 immunonegativity, (B) DMSO group, TLR4 immunonegativity, (C) I/R group, moderate TLR4 immunopositivity in renal tubule epithelial cells (arrowhead), (D) SCM-198 group, mild TLR4 immunopositivity in renal tubule epithelial cells (arrowhead).
(A) Control group, TLR4 immunonegativity, (B) DMSO group, TLR4 immunonegativity, (C) I/R group, moderate TLR4 immunopositivity in renal tubule epithelial cells (arrowhead), (D) SCM-198 group, mild TLR4 immunopositivity in renal tubule epithelial cells (arrowhead).

Figure 8

(A) Control group, Bax immunonegativity, (B) DMSO group, Bax immunonegativity, (C) I/R group, moderate Bax immunopositivity in renal tubule epithelial cells (arrowhead), (D) SCM-198 group, mild Bax immunopositivity in renal tubule epithelial cells (arrowhead).
(A) Control group, Bax immunonegativity, (B) DMSO group, Bax immunonegativity, (C) I/R group, moderate Bax immunopositivity in renal tubule epithelial cells (arrowhead), (D) SCM-198 group, mild Bax immunopositivity in renal tubule epithelial cells (arrowhead).

Figure 9

(A) Control group, severe Bcl-2 immunopositivity in renal tubule epithelial cells (arrowhead), (B) DMSO group, severe Bcl-2 immunopositivity in renal tubule epithelial cells (arrowhead), (C) I/R group, mild Bcl-2 immunopositivity in renal tubule epithelial cells, (D) SCM-198 group, moderate Bcl-2 immunopositivity in renal tubule epithelial cells (arrowhead).
(A) Control group, severe Bcl-2 immunopositivity in renal tubule epithelial cells (arrowhead), (B) DMSO group, severe Bcl-2 immunopositivity in renal tubule epithelial cells (arrowhead), (C) I/R group, mild Bcl-2 immunopositivity in renal tubule epithelial cells, (D) SCM-198 group, moderate Bcl-2 immunopositivity in renal tubule epithelial cells (arrowhead).

Figure 10

IHC scoring in renal tubule cells (A) LC3B, (B) Beclin-1, (C) TLR4, (D) Bax and (E) Bcl-2. *P<0.05 compared to control and DMSO groups, ϕP<0.05 compared to I/R group.
IHC scoring in renal tubule cells (A) LC3B, (B) Beclin-1, (C) TLR4, (D) Bax and (E) Bcl-2. *P<0.05 compared to control and DMSO groups, ϕP<0.05 compared to I/R group.
DOI: https://doi.org/10.2478/ebtj-2021-0025 | Journal eISSN: 2564-615X
Journal RSS Feed
Language: English
Page range: 161 - 169
Published on: Oct 21, 2021
Published by: European Biotechnology Thematic Network Association
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
SCM-198,
Renal ischemia-reperfusion,
Renal injury,
Inflammatory cytokines,
Autophagy,
Bax,
Bcl-2
Related subjects:
Life sciences,
Genetics,
Biotechnology,
Bioinformatics,
Life sciences, other

© 2021 Ersen Eraslan, Burak Bircan, Ayhan Tanyeli, Mustafa Can Güler, Yasin Bayır, Serdar Altun, published by European Biotechnology Thematic Network Association
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 5 (2021): Issue 4 (October 2021)Next article